Key Takeaways
- • Remedy's IPO pricing: Korean X-ray solutions company Remedy priced its initial public offering at 20,700 won per share, the upper end of its 17,800–27,700 won guidance range, with expected post-listing market capitalization of 157.1 billion won and total public offering proceeds of 24.8 billion won.
- • Exceptional institutional demand: The IPO generated a 1,146-to-1 subscription ratio from 2,246 domestic and foreign institutional investors, with 99.96% of participants offering prices at or above the upper end of the guidance range, signaling strong confidence in the company's growth prospects.
- • Capital allocation strategy: Remedy plans to deploy IPO proceeds toward R&D upgrades, production capacity expansion, and overseas sales network strengthening, including automation facilities and AI-integrated hardware solutions to capture demand in medical and industrial non-destructive testing markets.
- • Domestic M&A momentum: The article's headline references stretched domestic M&A activity, positioning Remedy's listing within a broader context of heightened capital market activity and increased dealmaking in the Korean economy during 2026.
Summary
Remedy, a medical device and industrial testing solutions company specializing in low-dose, ultra-compact X-ray technology, successfully completed its initial public offering on June 26, 2026, pricing shares at 20,700 won—the upper end of its target range. The company raised 24.8 billion won and achieved an anticipated market capitalization of 157.1 billion won following listing. KB Securities served as the listing organizer for the transaction.
The IPO demonstrated exceptional institutional demand, with 2,246 domestic and foreign institutional investors participating in the demand forecast period (June 17–23). The oversubscription reached 1,146 times, reflecting robust investor appetite. Notably, 99.96% of participating institutions bid at or above the upper end of the initial 17,800–27,700 won price guidance, indicating strong consensus on valuation and growth potential.
Remedy's capital deployment strategy reflects ambitions to scale both its medical device and industrial inspection portfolios. Proceeds will fund research and development enhancements, production capacity expansion through automation infrastructure, and geographic diversification of its sales operations. The company intends to integrate artificial intelligence solutions into its hardware product ecosystem, positioning itself to capture evolving demand in medical imaging and industrial non-destructive testing verticals. CEO Cho Bong-ho emphasized the company's intent to expand X-ray solution offerings in healthcare while establishing deeper penetration in the industrial inspection market.
The IPO reflects broader momentum in Korea's domestic capital markets during H1 2026, where domestic M&A and public capital raises have accelerated. Remedy's successful pricing at the high end of guidance and the exceptional institutional participation underscore investor appetite for technology-driven healthcare and industrial solutions companies during a period of market expansion.
The IPO demonstrated exceptional institutional demand, with 2,246 domestic and foreign institutional investors participating in the demand forecast period (June 17–23). The oversubscription reached 1,146 times, reflecting robust investor appetite. Notably, 99.96% of participating institutions bid at or above the upper end of the initial 17,800–27,700 won price guidance, indicating strong consensus on valuation and growth potential.
Remedy's capital deployment strategy reflects ambitions to scale both its medical device and industrial inspection portfolios. Proceeds will fund research and development enhancements, production capacity expansion through automation infrastructure, and geographic diversification of its sales operations. The company intends to integrate artificial intelligence solutions into its hardware product ecosystem, positioning itself to capture evolving demand in medical imaging and industrial non-destructive testing verticals. CEO Cho Bong-ho emphasized the company's intent to expand X-ray solution offerings in healthcare while establishing deeper penetration in the industrial inspection market.
The IPO reflects broader momentum in Korea's domestic capital markets during H1 2026, where domestic M&A and public capital raises have accelerated. Remedy's successful pricing at the high end of guidance and the exceptional institutional participation underscore investor appetite for technology-driven healthcare and industrial solutions companies during a period of market expansion.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.